Biocentury: Singapore’s next challenge: turning momentum into sustainable growth

Published on : 14th February 2024

Read about the key role of 65LAB in Singapore’s burgeoning ecosystem, as it seeks to advance academic projects through the steps towards company formation.

Singapore Venture Creation Group 65LAB Awards US$1.69 million to A*STAR-led Project Targeting the Cause of Vision Loss in Glaucoma and NAION

First 65LAB award to a project led by Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector R&D agency, extending support for

Singapore venture creation group 65LAB funds NUS novel biologics project targeting lung diseases

65LAB, a unique partnership of global investors ClavystBio, Leaps by Bayer, Lightstone Ventures, Polaris Partners and the Polaris Innovation Fund alongside Evotec, has funded

65LAB awards US$1.5 million to Duke-NUS platform to advance antifibrotic drug discovery

Recipient Professor Enrico Petretto from Duke-NUS is spearheading groundbreaking research to develop new drugs for lung disease and uncover new therapeutic targets for kidney